open access

Vol 80, No 12 (2022)
Expert opinion
Get Citation

Rules for using reduced doses of non-vitamin K antagonist oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation. The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society

Iwona Gorczyca-Głowacka1, Agnieszka Kapłon-Cieślicka2, Marcin Wełnicki3, Filip Szymański4, Marcin Barylski5, Artur Mamcarz3, Krzysztof J Filipiak6, Beata Wożakowska-Kapłon17
DOI: 10.33963/KP.a2022.0286
·
Pubmed: 36601886
·
Kardiol Pol 2022;80(12):1299-1306.
Affiliations
  1. Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland
  2. 1st Chair and Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
  3. 3rd Department of Internal Diseases and Cardiology, Medical University of Warsaw, Warszawa, Poland
  4. Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Warszawa, Poland
  5. Department of Internal Diseases and Cardiac Rehabilitation, Medical University of Lodz, Łódź, Poland
  6. Institute of Clinical Sciences, Maria Skłodowska-Curie Medical Academy in Warsaw, Warszawa, Poland
  7. 1st Clinic of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center in Kielce, Kielce, Poland

open access

Vol 80, No 12 (2022)
Expert opinion and position paper

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Rules for using reduced doses of non-vitamin K antagonist oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation. The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 80, No 12 (2022)

Article type

Expert opinion

Pages

1299-1306

Page views

550

Article views/downloads

125

DOI

10.33963/KP.a2022.0286

Pubmed

36601886

Bibliographic record

Kardiol Pol 2022;80(12):1299-1306.

Authors

Iwona Gorczyca-Głowacka
Agnieszka Kapłon-Cieślicka
Marcin Wełnicki
Filip Szymański
Marcin Barylski
Artur Mamcarz
Krzysztof J Filipiak
Beata Wożakowska-Kapłon

References (24)
  1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498.
  2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151.
  3. Halperin JL, Hankey GJ, Wojdyla DM, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
  4. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–992.
  5. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021; 23(10): 1612–1676.
  6. Steinberg BA, Shrader P, Pieper K, et al. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc. 2018; 7(4).
  7. Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016; 150(6): 1302–1312.
  8. Rasmussen LH, Larsen TB, Graungaard T, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012; 60(8): 738–746.
  9. Lip GYH, Clemens A, Noack H, et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014; 111(5): 933–942.
  10. Nielsen PB, Skjøth F, Søgaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017; 356: j510.
  11. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019; 41(3): 407–477.
  12. Gorczyca I, Jelonek O, Uziębło-Życzkowska B, et al. Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry. J Clin Med. 2020; 9(11).
  13. Yu HT, Yang PS, Jang E, et al. Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2020; 9(12): e014177.
  14. García Rodríguez LA, Martín-Pérez M, Vora P, et al. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. BMJ Open. 2019; 9(9): e031341.
  15. Yao X, Shah ND, Sangaralingham LR, et al. Non-Vitamin k antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017; 69(23): 2779–2790.
  16. Ono T, Ikemura N, Kimura T, et al. Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: A cross-sectional analysis of a multicenter outpatient registry. J Cardiol. 2019; 73(1): 14–21.
  17. Jacobs MS, van Hulst M, Campmans Z, et al. Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions. Neth Heart J. 2019; 27(7-8): 371–377.
  18. Pharithi RB, Ranganathan D, O'Brien J, et al. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. Ir J Med Sci. 2019; 188(1): 101–108.
  19. Chan YH, Chao TF, Lee HF, et al. Impacts of different renal function estimation formulas on dosing of DOACs and clinical outcomes. J Am Coll Cardiol. 2020; 76(15): 1808–1810.
  20. Li W, Zhou Y, Chen S, et al. Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis. Front Cardiovasc Med. 2022; 9: 1005742.
  21. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019; 54(3).
  22. Windecker S, Lopes RD, Massaro T, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019; 380(16): 1509–1524.
  23. Ten Berg JM, de Veer A, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377(16): 1513–1524.
  24. Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015; 169(4): 472–8.e5.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl